Topics

No keywords indexed for this article. Browse by subject →

References
30
[1]
Berntorp "Consensus perspectives on prophylactic therapy for haemophilia: summary statement" Haemophilia (2003) 10.1046/j.1365-2516.9.s1.17.x
[2]
Manco‐Johnson "Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia" N Engl J Med (2007) 10.1056/nejmoa067659
[3]
Feldman "Tailored frequency‐escalated primary prophylaxis for severe haemophilia A: results of the 16‐year Canadian Hemophilia Prophylaxis Study longitudinal cohort" Lancet Haematol (2018) 10.1016/s2352-3026(18)30048-6
[4]
Petrini "What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?" Haemophilia (2001) 10.1111/j.1365-2516.2001.00471.x
[5]
Wu "Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China" Haemophilia (2011) 10.1111/j.1365-2516.2010.02348.x
[6]
Blanchette "Definitions in hemophilia: communication from the SSC of the ISTH" J Thromb Haemost (2014) 10.1111/jth.12672
[7]
Fischer "When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH" J Thromb Haemost (2016) 10.1111/jth.13298
[8]
Zhou "Burden of illness: direct and indirect costs among persons with hemophilia A in the United States" J Med Econ (2015) 10.3111/13696998.2015.1016228
[9]
Oladapo "Health‐related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials" Haemophilia (2015) 10.1111/hae.12759
[10]
Buchbinder "What is the role of prophylaxis in the improvement of health‐related quality of life of patients with hemophilia?" Hematology Am Soc Hematol Educ Program (2013) 10.1182/asheducation-2013.1.52
[11]
Fischer "RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia" Haemophilia (2007) 10.1111/j.1365-2516.2007.01521.x
[12]
Carneiro "Comparing the burden of illness of hemophilia between resource‐constrained and unconstrained countries: the São Paulo‐Toronto Hemophilia Study" Haemophilia (2017) 10.1111/hae.13230
[13]
McCusker "International Cross Cultural Validation Study of the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT)" Haemophilia (2015) 10.1111/hae.12597
[14]
Villaça "Validity of the Portuguese CHO‐KLAT in Brazil" Haemophilia (2016) 10.1111/hae.13031
[15]
Wu "A prospective study of health‐related quality of life of boys with severe haemophilia A in China: comparing on‐demand to prophylaxis treatment" Haemophilia (2017) 10.1111/hae.13198
[16]
Wu "Validation of the Chinese version of the Canadian Haemophilia Outcomes–Kids’ Life Assessment Tool (the CHO‐KLAT)" Health Qual Life Outcomes (2014)
[17]
Young "How well does the Canadian Haemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) measure the quality of life of boys with haemophilia?" Pediatr Blood Cancer (2006) 10.1002/pbc.20618
[18]
Young "Cross‐cultural validation of the CHO‐KLAT and HAEMO‐QoL‐A in Canadian French" Haemophilia (2012) 10.1111/j.1365-2516.2011.02703.x
[19]
Young "Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT Version 2.0)" Value Health (2013) 10.1016/j.jval.2013.02.004
[20]
Wharfe "The Jamaican Haemophilia Registry: describing the burden of disease" Haemophilia (2018) 10.1111/hae.13517
[21]
Young "Development of a health‐related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT)" Haemophilia (2004) 10.1111/j.1355-0691.2004.00877.x
[22]
White "Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis" Thromb Haemost (2001) 10.1055/s-0037-1615621
[23]
Snijders "Modeled variance in two‐level models" Sociol Methods Res (1994) 10.1177/0049124194022003004
[24]
Interpretation of Changes in Health-related Quality of Life

Geoffrey R. Norman, Jeff A. Sloan, Kathleen W. Wyrwich

Medical Care 2003 10.1097/01.mlr.0000062554.74615.4c
[25]
World Federation of Hemophilia. Report on the Global Survey 2004: World Federation of Hemophilia; 2005. [Accessed 2018 Feb 6]. Available from http://www1.wfh.org/publication/files/pdf-1433.pdf
[26]
World Federation of Hemophilia Report on the Annual Global Survey 2010‐2011. [Accessed 2018 Feb 6]. Available from https://www1.wfh.org/publication/files/pdf-1427.pdf
[27]
World Federation of Hemophilia. Report on the Annual Global Survey 2011–2012. [Accessed 2018 Feb 6]. Available from http://www1.wfh.org/publication/files/pdf-1488.pdf
[28]
World Federation of Hemophilia. Report on the Annual Global Survey 2015–2016. [Accessed 2018 Feb 6]. Available from https://www1.wfh.org/publication/files/pdf-1669.pdf
[29]
Limperg "Health‐related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties" Haemophilia (2017) 10.1111/hae.13197
[30]
Tang "Short‐term low‐dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi‐centre pilot study in China" Haemophilia (2013) 10.1111/j.1365-2516.2012.02926.x